GUPS 肾脏肿瘤更新:现有WHO实体新进展与分子概念演变
泌尿病理学会(GUPS)综述2016年WHO分类后肾脏肿瘤进展,更新现有实体的诊断标准、分子相关性与命名。透明细胞RCC预后仍依据WHO/ISUP分级、AJCC/pTNM分期、凝固性坏死及横纹肌样和肉瘤样分化;乳头状RCC不再推荐亚型分型;提出低恶性潜能嗜酸细胞性肾肿瘤等新术语。
要点
- 透明细胞RCC预后因素包括WHO/ISUP分级、AJCC/pTNM分期、凝固性坏死、横纹肌样和肉瘤样分化。
- 乳头状RCC不再推荐亚型分型,WHO/ISUP分级和肿瘤结构更能预测结局。
- 难以分类的RCC尤其嗜酸细胞形态年轻患者,推荐低阈值行FH、2SC和SDHB免疫组化。
核心结论
- GUPS更新了2016年WHO分类后肾脏肿瘤的现有实体诊断标准、分子相关性和命名。
- 透明细胞RCC的预后仍由WHO/ISUP分级、AJCC/pTNM分期、凝固性坏死及横纹肌样和肉瘤样分化决定。
- 乳头状RCC亚型分型不再推荐,WHO/ISUP分级和肿瘤结构更好预测结局。
研究设计与样本
- GUPS对2016年WHO分类后肾脏肿瘤学进展进行综述,提供现有实体更新。
主要发现
- 透明细胞RCC亚克隆遗传改变包括SETD2、PBRM1、BAP1及14q和9p缺失,与不同预后、转移模式和治疗脆弱性相关。
- 新乳头状RCC变异型/模式包括双相型、实性型、Warthin样型和反向极性乳头状肾肿瘤。
- 嗜酸细胞瘤与嫌色细胞RCC之间「交界性」肿瘤提出术语「低恶性潜能嗜酸细胞性肾肿瘤,未进一步分类」。
- 透明细胞乳头状RCC可能需重新分类为低恶性潜能肿瘤;管状囊性RCC仅在形态纯粹时诊断。
- MiTF家族易位RCC形态和融合伴侣多样;TFEB扩增RCC见于老年患者且侵袭性更强。
关键数值与推荐
- 获得性囊性疾病(ACD)RCC样囊肿可能是ACD-RCC的前驱病变。
- 肾髓样癌诊断需SMARCB1(INI-1)表达阴性且伴镰状细胞特质/疾病。
- 黏液性管状和梭形细胞癌(MTSCC)可通过1、4、6、8、9、13、14、15和22号染色体缺失与形态重叠的乳头状RCC区分。
- 伴不良组织学特征的MTSCC常见CDKN2A/2B(9p)缺失。
- BRAF突变统一了后肾家族肿瘤;推荐术语「FH缺陷型RCC」优于「遗传性平滑肌瘤病和RCC综合征相关RCC」。
临床怎么用
- 透明细胞RCC报告应包含WHO/ISUP分级、AJCC/pTNM分期、凝固性坏死及横纹肌样和肉瘤样分化。
- 乳头状RCC不再进行亚型分型,应报告WHO/ISUP分级和肿瘤结构。
- 难以分类的RCC尤其嗜酸细胞形态年轻患者,低阈值行FH、2SC和SDHB免疫组化。
- 肾髓样癌诊断需确认SMARCB1(INI-1)表达阴性和镰状细胞特质/疾病。
- 管状囊性RCC仅在形态纯粹时诊断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Genitourinary Pathology Society (GUPS) reviewed recent advances in renal neoplasia, particularly post-2016 World Health Organization (WHO) classification, to provide an update on existing entities, including diagnostic criteria, molecular correlates, and updated nomenclature. Key prognostic features for clear cell renal cell carcinoma (RCC) remain WHO/ISUP grade, AJCC/pTNM stage, coagulative necrosis, and rhabdoid and sarcomatoid differentiation. Accrual of subclonal genetic alterations in clear cell RCC including SETD2, PBRM1, BAP1, loss of chromosome 14q and 9p are associated with variable prognosis, patterns of metastasis, and vulnerability to therapies. Recent National Comprehensive Cancer Network (NCCN) guidelines increasingly adopt immunotherapeutic agents in advanced RCC, including RCC with rhabdoid and sarcomatoid changes. Papillary RCC subtyping is no longer recommended, as WHO/ISUP grade and tumor architecture better predict outcome. New papillary RCC variants/patterns include biphasic, solid, Warthin-like, and papillary renal neoplasm with reverse polarity. For tumors with 'borderline' features between oncocytoma and chromophobe RCC, a term "oncocytic renal neoplasm of low malignant potential, not further classified" is proposed. Clear cell papillary RCC may warrant reclassification as a tumor of low malignant potential. Tubulocystic RCC should only be diagnosed when morphologically pure. MiTF family translocation RCCs exhibit varied morphologic patterns and fusion partners. TFEB-amplified RCC occurs in older patients and is associated with more aggressive behavior. Acquired cystic disease (ACD) RCC-like cysts are likely precursors of ACD-RCC. The diagnosis of renal medullary carcinoma requires a negative SMARCB1 (INI-1) expression and sickle cell trait/disease. Mucinous tubular and spindle cell carcinoma (MTSCC) can be distinguished from papillary RCC with overlapping morphology by losses of chromosomes 1, 4, 6, 8, 9, 13, 14, 15, and 22. MTSCC with adverse histologic features shows frequent CDKN2A/2B (9p) deletions. BRAF mutations unify the metanephric family of tumors. The term "fumarate hydratase deficient RCC" ("FH-deficient RCC") is preferred over "hereditary leiomyomatosis and RCC syndrome-associated RCC". A low threshold for FH, 2SC, and SDHB immunohistochemistry is recommended in difficult to classify RCCs, particularly those with eosinophilic morphology, occurring in younger patients. Current evidence does not support existence of a unique tumor subtype occurring after chemotherapy/radiation in early childhood.
引用
- Trpkov K, Hes O, Williamson SR, et al. New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Mod Pathol. 2021. PMID: 33664427. doi:10.1038/s41379-021-00779-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。